Pacira Biosciences, Inc.
Could not find a ticker for this position, may be a filing error
Pacira BioSciences makes non-opioid pain treatments, best known for EXPAREL, a long-acting local anesthetic injected at the surgical site so patients recover from operations with less reliance on opioids. Its lineup also includes iovera°, a device that uses targeted cold to numb nerves. Founded in 2006 under the placeholder name Blue Acquisition Corp., the Tampa-based company later renamed itself Pacira and rebranded as Pacira BioSciences in 2019.
0.75% Convertible Senior Notes due August 1, 2025
Granted 711.3K · Bought 8.3K
Granted 207.9K · Sold 16.9K
Granted 221.7K · Sold 45.2K
Granted 88.4K · Sold 2.0K
Granted 174.1K · Sold 62.1K
Granted 106.1K
Granted 71.2K · Sold 21.1K
Granted 12.2K
Granted 11.4K
Granted 17.8K · Bought 1.0K
Granted 17.8K · Bought 1.4K · Sold 500
Granted 17.8K
Sold 119.3K
Granted 17.8K · Bought 2.0K
Granted 17.8K · Bought 4.9K · Sold 4.9K
Granted 17.8K
Granted 5.2K · Sold 880
Granted 11.4K · Sold 2.4K
Granted 6.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lee Frank D.Chief Executive Officer, Director · 7 transactions | — | 660.8K | 711.3K | 8.3K | — |
| Slonin JonathanChief Medical Officer · 20 transactions | +502.7% | 218.9K | 207.9K | — | 16.9K |
| Williams KristenChief Administrative Officer · 12 transactions | — | 167.1K | 221.7K | — | 45.2K |
| Gaugler DarylChief Operating Officer · 8 transactions | +266% | 115.4Kas of Dec 2024 | 88.4K | — | 2.0K |
| Cross ShawnChief Financial Officer · 16 transactions | — | 105.3K | 174.1K | — | 62.1K |
| Teehan BrendanChief Commercial Officer · 4 transactions | — | 100.9K | 106.1K | — | — |
| Riker LaurenSenior Vice President, Finance · 15 transactions | — | 62.3K | 71.2K | — | 21.1K |
| Reinhart Charles A. IIIChief Financial Officer · 2 transactions | +21.7% | 51.9Kas of Jun 2024 | 12.2K | — | — |
| Kronenfeld Mark A.Director · 2 transactions | +57.9% | 31.1Kas of Jun 2025 | 11.4K | — | — |
| Brege LauraDirector · 4 transactions | +166% | 30.1K | 17.8K | 1.0K | — |
| Froimson MarkDirector · 5 transactions | +238.4% | 26.5K | 17.8K | 1.4K | 500 |
| Christie ChristopherDirector · 3 transactions | +338.3% | 23.1K | 17.8K | — | — |
| Pace Gary WDirector · 3 transactions | -84.4% | 22.1Kas of Mar 2024 | — | — | 119.3K |
| Yang Michael J.Director · 4 transactions | — | 19.8K | 17.8K | 2.0K | — |
| Bigal MarceloDirector · 6 transactions | — | 17.8K | 17.8K | 4.9K | 4.9K |
| Young AlethiaDirector · 3 transactions | — | 17.8K | 17.8K | — | — |
| Hastings Paul JDirector · 2 transactions | +51.9% | 12.7Kas of Jun 2024 | 5.2K | — | 880 |
| Ceesay AbrahamDirector · 3 transactions | — | 9.0K | 11.4K | — | 2.4K |
| Hirawat SamitDirector · 1 transaction | — | 6.4K | 6.4K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: -257.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.